PSRNs not only enhance the degradation of target proteins both in vitro and in vivo in colorectal cancer (CRC) but also augment the efficacy of immune checkpoint blockades (ICBs) by upregulating PD-L1 expression in cancer cells and inhibiting regulatory T cell proliferation within the tumor microenvironment, thereby achieving enhanced anti-tumor effects in the CT26 tumor model [129]. Here, CD274 is linked to neoplasm.